Psoriasis and the Risk of Cardiovascular Disease. A Prospective Study
PsoriasisCardiovascular DiseaseThere is growing evidence that psoriasis is a systemic disorder which enhances atherosclerosis and the risk of cardiovascular disease. Epidemiological studies have shown an independent association between psoriasis and atherosclerosis, stroke and coronary artery disease. The main goal of this on-going study is to register data which will enable the identification of new markers of atherosclerosis activity and carotid plaque instability in patients with severe psoriasis.
Prevalence of Psoriasis Alba in Psoriatic Patients
PsoriasisInterdigital psoriasis (psoriasis alba) is atypical and rare form of psoriasis that is often missed as it is commonly mistaken for either dermatoses or fungal infection.In this study we observed and analyzed the prevalence of psoriasis interdigital of palms and soles and brought medical awareness to dermatologists and family doctors this rare form of psoriasis. Thus, you can help to avoid mistaken diagnosis and the start of correct treatment as soon as possible.
A Clinical Study of Subclinical Enthesitis and Synovitis in Patients With Vulgaris Psoriasis
Vulgaris PsoriasisA clinical study of subclinical enthesitis and synovitis in patients with vulgaris psoriasis
The RATIO: Registry of Infections and Lymphoma in Patients Treated With TNF-a Antagonists
Rheumatoid ArthritisCrohn's Disease2 moreThe RATIO registry is a French registry designed by a multidisciplinary group to collect data on opportunistic and severe bacterial infections and lymphoma in patients treated with TNF-a antagonists ( infliximab, etanercept and adalimumab). A total of 486 medical units in metropolitan France participate in the RATIO registry. All diagnosis are retained after validation by 2 qualified infectious disease or haematologist physicians (on the basis of the standardized case report form, the hospitalisation summary, and the microbiological and radiological results). Risk factors for developing these conditions when treated by TNF-a antagonists will be identified in a case control study. Incidence of these diseases will be calculated.